HCA Healthcare, Inc. (HCA) Stock Price & How to Invest

HCA Healthcare is the largest for-profit hospital system in the United States, operating a network of acute-care hospitals alongside surgery centers, urgent-care clinics, freestanding emergency rooms, and physician clinics. Its strategy centers on building dense local networks in growing Sun Belt and suburban markets, where controlling a large share of care lets it negotiate better rates with commercial insurers, recruit physicians, and spread fixed costs. In the first quarter of 2026 HCA reported revenue of about $19.1 billion, up roughly 4% year over year, with net income near $1.6 billion and diluted EPS of about $7.15. Equivalent admissions rose modestly and revenue per admission grew faster, and the company reaffirmed full-year 2026 guidance of roughly $76.5 billion to $80.0 billion in revenue and $15.55 billion to $16.45 billion in adjusted EBITDA.

The defining issue for 2026 is reimbursement policy. HCA has warned that the lapse of enhanced ACA marketplace subsidies plus Medicaid payment changes could pressure adjusted EBITDA by several hundred million dollars, with a $150 million ACA-related hit already flagged in the first quarter. Management is running a multi-year resilience plan to offset part of the impact through cost control, productivity, and pricing. At the same time HCA is accelerating its outpatient shift, adding lower-cost ambulatory sites, and rolling out the Meditech Expanse electronic-record system across its facilities. It remains a heavy generator of free cash flow, which it directs toward capital projects, dividends, and large share repurchases.

The dominant risk is reimbursement and health-care policy. HCA depends on a mix of commercial, Medicare, and Medicaid payers, and the expiration of enhanced ACA marketplace subsidies plus Medicaid payment changes could pressure adjusted EBITDA by several hundred million dollars, with more uninsured and self-pay patients raising bad-debt and charity-care costs. Labor is a structural cost pressure: nursing and physician wages, contract-labor use, and staffing shortages can compress margins quickly. Supply, drug, and equipment costs, including exposure to tariffs and supply-chain disruption, add further cost volatility. HCA also carries substantial debt from years of buybacks, so higher interest rates raise financing costs. Litigation, regulatory scrutiny of billing and pricing practices, and local competition from nonprofit systems and physician-owned outpatient centers round out the risk set.

21 analysts publish price targets on HCA, averaging $453.38 against a $402.59 price as of August 2026, or +12.6%. The published targets run from $380.00 to $579.00, a moderate spread, and the ratings split 14 buy, 10 hold, 1 sell. Over the last six months there have been 0 raises and 11 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full HCA forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on HCA Healthcare, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Scale and local-market density. HCA's core advantage is its size and its strategy of dominating individual markets rather than spreading thin. The most optimistic published target, $579.00, assumes this works close to its best case.

The case against. The dominant risk is reimbursement and health-care policy. The most pessimistic target, $380.00, is roughly what HCA is worth if this bites instead.

Read the full bull and bear case on HCA, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see HCA Healthcare, Inc.'s investor relations page or your broker.

• Revenue (Q1 2026): ~$19.1 billion, up ~4% year over year
• Full-year 2026 revenue guidance: ~$76.5 billion to $80.0 billion (reaffirmed)
• Adjusted EBITDA guidance (2026): ~$15.55 billion to $16.45 billion
• Net income (Q1 2026): ~$1.6 billion, or ~$7.15 per diluted share
• Profitability: High-single-digit net margin, strong free cash flow generation
• Balance sheet: Substantial debt load built up through years of buybacks

Figures are approximate and tied to the asOf date; verify live numbers before acting. HCA is generally valued as a steady, cash-generative operator rather than a high-growth stock, so its multiple reflects reimbursement stability and buyback-driven per-share growth more than rapid revenue expansion. The biggest variable is policy: the 2026 guidance already bakes in an ACA-subsidy and Medicaid hit that management is partly offsetting, so how those headwinds actually land matters more to the earnings picture than the headline multiple.

If you want HCA exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to HCA: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get HCA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (COWZ), which spreads the position across many companies. Or build it into a focused thematic portfolio, so HCA sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where HCA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

HCA is the scale leader in US hospital care, generating large, steady cash flows it returns to shareholders, but its earnings are exposed to reimbursement policy. In 2026 it is absorbing an ACA-subsidy and Medicaid hit while leaning into outpatient growth, so the question is how it navigates policy headwinds.

Whether HCA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is HCA a buy or a sell?, and where the stock could go from here in the HCA stock forecast.

For income investors, whether HCA pays a dividend and how the payout looks is covered in does HCA pay a dividend? And to weigh HCA against a peer, read the full side-by-side comparisons: HCA vs THC and HCA vs UHS.